TABLE 8.
Tumor type | Drug resistance | Mechanisms | References |
Adenocarcinoma | Paclitaxel | Platelets secreting thrombospondin-1, and RANTES, modulating cancer cell cycle, DNA damage repair pathways and MAPK levels. | Radziwon-Balicka et al., 2012 |
HCC | Multikinase inhibitor | Platelets derived growth factors such as PDGF, TGF-α and -β, EGF and serotonin, regulating the sensitivity and resistance to multikinase inhibitors. | D’Alessandro et al., 2015 |
NSCLC | Cisplatin | Platelets rescuing cisplatin-induced apoptosis via the Akt/Bad/Bcl-2 signaling pathway. | Wang Z. et al., 2018 |
Pancreatic cancer | Cisplatin | Platelets releasing TGF-β, activating PI3K/Akt and MEK/Erk signaling. | Chen et al., 2013 |
HCC, hepatocellular carcinoma; PDGF, platelet-derived growth factor; EGF, epidermal growth factor; NSCLC, non-small cell lung cancer.